MetaVia's DA-1726 Shows 9.1% Weight Loss in Phase 1 Trial, Boosting Obesity and MASH Prospects
Event summary
- MetaVia presented Phase 1 data for DA-1726 at EASL 2026, showing 9.1% mean body weight reduction at 48 mg dose without titration.
- Exploratory FibroScan assessments demonstrated early liver-related improvements, including reductions in liver stiffness and CAP scores.
- DA-1726 was generally well tolerated with no serious adverse events or treatment-related discontinuations observed.
- Ongoing Phase 1 Part 3a/3b titration studies continue to evaluate extended treatment at higher-dose levels.
The big picture
MetaVia's Phase 1 results for DA-1726 reinforce its potential as a next-generation treatment for obesity and MASH, addressing a growing market need for effective cardiometabolic therapies. The dual agonist mechanism offers a strategic advantage over selective GLP-1 receptor agonists, positioning DA-1726 as a potential best-in-class candidate. The ongoing titration studies will be critical in assessing the drug's long-term efficacy and safety profile.
What we're watching
- Clinical Efficacy
- Whether DA-1726 can sustain progressive weight loss and liver-related improvements in longer-term studies.
- Regulatory Pathway
- The pace at which MetaVia can advance DA-1726 through subsequent clinical phases and potential regulatory approval.
- Competitive Positioning
- How DA-1726's differentiated profile as a dual GLP-1 and glucagon receptor agonist will position it against existing and emerging obesity and MASH treatments.
Related topics